RX Biosyent Inc

BioSyent Inc. ("BioSyent")(TSX VENTURE:RX) announces that it has established a
new Hospital Products Division focused on licensing or acquiring pharmaceutical
products used primiarily in a hospital setting, and marketing those products
across Canada.


The Hospital Products Division of BioSyent Pharma Inc. has licensed
Ciprofloxacin Injection, an anti-bacterial agent, for the Canadian market.
Ciprofloxacin Injection is a generic equivalent to CIPRO I.V. Minibags 2mg/ml
from Bayer Inc. on which the remaining patents expired recently.


BioSyent Pharma has launched Ciprofloxacin Injection to the Canadian market and
has secured its first supply contract and order for the product.


BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source
products that have been successfully developed and proven to be safe and
effective; manage these products through the regulatory process and product
registration (approval); and once approved, market these products in Canada.
These pharmaceuticals will compete in both the branded and generic market
segments and will not require further product development investment other than
regulatory costs.


BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly
owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences
pharmaceutical products and markets these products in Canada. Wholly owned
BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy
business marketing bio and health friendly non-chemical insecticides. BioSyent
common shares are listed for trading on the TSX Venture Exchange (TSXV) under
the symbol RX.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements.  Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024